Top 4 High-Yield Dividend Stocks to Add to Your Portfolio

Will falling free cash flow end this drug giant's streak? ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

AN OXFORD CLUB PUBLICATION

View in browser SPONSORED PROOF: New One Ticker (Weekly) Payouts A multimillionaire stock trader's research explains how focusing on just one ticker every week has generated payouts up to a rare 2,614% in under 11 days... AND he's brought proof to show the world! SEE THE PROOF SAFETY NET The (Almost) Unforgivable Sin Marc Lichtenfeld, Chief Income Strategist, The Oxford Club Bristol Myers Squibb (NYSE: BMY) is a $100 billion market cap pharmaceutical company that has raised its dividend every year since 2010 and has paid one since 1933. The stock currently yields 4.5%. But can it continue to pay its $0.57 per share quarterly dividend despite an expected decline in its free cash flow next year? Bristol Myers Squibb has 35 approved drugs, including well-known names like blood thinner Eliquis and cancer fighters Opdivo and Revlimid. This year, revenue and earnings are forecast to dip, though free cash flow is projected to grow considerably from 2022's total. However, next year, while earnings are expected to recover, free cash flow will drop, according to Wall Street analysts. In the Safety Net model, there is no sin bigger than falling cash flow. SPONSORED BREAKING: Tiny Biotech Successfully Treats Blindness There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return. Get the Details Here >>> However, the drug giant's other numbers are very solid. The company will likely pay out about $4.6 billion in dividends this year, which is just 30% of its expected free cash flow. Next year's predicted $4.8 billion in dividend payouts should result in a payout ratio of just 33%. With all of this in mind, how do you feel about the company's ability to pay its dividend? Is a decline in free cash flow a deal-breaker for you? Let me know how you'd grade Bristol Myers Squibb's dividend safety in the comments section on the next page, and then scroll up to reveal my grade. REVEAL MY GRADE RECOMMENDED LINKS Wall Street PROJECTS $30 Energy Stock Will Rise to $280 in 18 Months! Expert Predicts Gold, Oil, Copper About to Soar Higher... Discover Why We're in a New Commodities Supercycle Right Here. MORE FROM WEALTHY RETIREMENT Why We Won't See a Stock Market Crash Anytime Soon Charitable Giving: Giving Back This Holiday Season 3 Retail Stocks Set for a "Black Friday Boost" Financial Lessons to Be Thankful For Facebook LinkedIn Email Share Push Alert SPONSORED Upcoming Supply Shortages... "Worse Than Ukraine" If China succeeds in this new evil plot... we would almost surely see shortages in America that would be "worse than Ukraine"... With new cars... phones... appliances... pacemakers... and military equipment becoming virtually impossible to obtain. Even The New York Times admits that we'd see a "grinding halt to the electronic supply chains that make the modern world run." A top global financial insider just exposed all the details of China's sinister plan... And the #1 thing you should be doing with your assets before it's too late. [SEE THE DETAILS] You are receiving this email because you subscribed to Wealthy Retirement. Wealthy Retirement is published by The Oxford Club. Questions? Check out our FAQs. Trying to reach us? Contact us here. Please do not reply to this email as it goes to an unmonitored inbox. Privacy Policy | Whitelist Wealthy Retirement | Unsubscribe © 2023 The Oxford Club, LLC All Rights Reserved The Oxford Club | 105 West Monument Street | Baltimore, MD 21201 North America: 877.808.9795 | International: +1.443.353.4621 Oxfordclub.com Nothing published by The Oxford Club should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed personalized investment advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after publication before trading on a recommendation. Any investments recommended by The Oxford Club should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of The Oxford Club, LLC, 105 West Monument Street, Baltimore, MD 21201.